What Astrea does

Astrea Pharma is a French pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 2022 and headquartered in Fontaine-lès-Dijon, France. The company operates three wholly-owned manufacturing sites in Fontaine-lès-Dijon, Monts, and Amilly, delivering both Oral Solid Dose (OSD) and aseptic sterile manufacturing services to pharmaceutical company clients across more than 100 countries. Its OSD platform supports capsules, tablets, film-coated tablets, micro tablets, pellets, microspheres, and powders, using dry, wet, and spray granulation with mixing capacities from 50 to 2000 liters; its sterile platform provides aseptic filling of vials (2-100mL) and cartridges (1.5-3mL) at speeds up to 200 units per minute, with terminal sterilization, 100% Container Closure Integrity Testing, and cold-chain storage from -80°C to +5°C.

Astrea's technology stack spans development through commercial supply, including in-house analytical capabilities (HPLC, UHPLC, GC-FID, IR, UV, microbiological and physico-chemical testing, stability chambers), full serialization and aggregation, and tech-transfer project management. Regulatory approvals from ANSM (EU GMP), US FDA, KFDA (Korea), ANVISA (Brazil), MoH (Russia), HA (Belarus), SFDA (Saudi Arabia), and ISO 14001 enable global commercial supply. The company complements manufacturing with regulatory affairs (CP/DCP/MRP/NS submissions), life cycle management, product reformulation, and packaging design services.

Astrea generates revenue through enterprise B2B contracts — long-term, quote-based manufacturing and development engagements — sold via direct enterprise field sales. Customer relationships are positioned as multi-year and tailor-made, with services integrated into clients' strategic planning. The company employs 101-250 staff, markets itself primarily through its corporate website and LinkedIn, and emphasizes a roll-up-style growth model anchored by a leadership team with 75+ years of combined pharma industrial and M&A experience.

Name

Astrea

Legal name

Astrea Pharma

Website

https://astreapharma.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

101–250 employees

Short description

Astrea Pharma is a French pharmaceutical CDMO operating three manufacturing sites in France, providing oral solid dose and aseptic sterile contract manufacturing plus regulatory, tech transfer, and life cycle management services to pharmaceutical companies across 100+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Fontaine-lès-dijon

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Astrea generates revenue through contract development and manufacturing services for pharmaceutical products. As a CDMO, they provide development, manufacturing, packaging, and supply services under long-term customer contracts. The company offers services from development through commercial supply across OSD and sterile dosage forms.
2. Regulatory Support Services: Additional revenue streams include regulatory services such as Marketing Authorization Applications, post-marketing authorization maintenance, and technical dossier preparation.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Astrea is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing drug product development, manufacturing, packaging, and supply services across Oral Solid Dose (OSD) and Aseptic Sterile dosage forms. The company delivers tailor-made, long-term contract manufacturing solutions from early-stage development through commercial supply, supported by regulatory affairs, tech transfer, life cycle management, and storage/distribution services to over 100 countries.

Product overview

Astrea is a world-class, customer-focused CDMO (Contract Development and Manufacturing Organization) dedicated to the pharmaceutical supply chain. The company operates two core manufacturing platforms: OSD (Oral Solid Dose) covering tablets, capsules, film-coated tablets, micro tablets, pellets, microspheres and powders; and Steriles for aseptic filling of vials and cartridges with terminal sterilization capabilities. These are supported by a comprehensive suite of services including Product Development, Regulatory Support, Tech Transfer, Project Management, Life Cycle Management, and Storage & Distribution. The company operates three manufacturing sites in France (Astrea Fontaine, Astrea Monts, Astrea Amilly) with regulatory approvals from ANSM (EU GMP), US FDA, KFDA, ANVISA, and other global authorities.

Differentiator

Problem solved

Functional benefit

Products and services

• OSD (Oral Solid Dose) Manufacturing Contract manufacturing of oral solid dose pharmaceutical products, including dry granulation by roller compaction, wet granulation (horizontal and vertical mixer/granulator), spray granulation, mixing from 50–2000L, solvents handling, and prilling. Dosage forms produced include capsules, tablets, film-coated tablets (with solvents handling), micro tablets, pellets, microspheres, and powders. Includes analytical capabilities (HPLC, UHPLC, GC-FID, HS injector, Dissolutest type I/II/IV, IR, UV spectro, potentiometry, laser granulometer) plus packaging (blisters including Alu-Alu, bottles, bulk containers, sachets, stick packs) with serialization and aggregation. For pharmaceutical companies requiring oral solid dose contract manufacturing.
• Steriles (Aseptic Manufacturing) Contract aseptic filling of vials (2 to 100mL) and cartridges (1.5 & 3mL), terminal sterilization, and filling of temperature- and/or oxygen-sensitive products at speeds up to 200 units/min with stainless steel or fully disposable filling set-up. Includes 100% CCIT (HVLD), semi-automated and automated visual inspection, automated packaging (1-5-10 pack), and serialization and aggregation. Analytical capabilities include microbiology (sterility testing, bioburden, endotoxins), physico-chemical (HPLC, UPLC, GPC, SAA, IR spectroscopy), and stability testing in climatic chambers. Storage and distribution under ambient, cold, and freeze conditions. EU & FDA approved site. For pharmaceutical companies requiring aseptic contract manufacturing.
• Product Development Services Drug product development support from pre-formulation through late-stage manufacturing, spanning both OSD and Sterile dosage form technologies. For pharmaceutical companies needing early-stage development expertise.
• Life Cycle Management Services Support for established products across a broad range of life cycle management projects including update/redevelopment (reformulation, production process optimization, analytical method development and validation), redesign-to-cost programs, and pack design optimization. For pharmaceutical companies managing mature or established products.
• Regulatory Support Services Regulatory services including due diligence and strategy, marketing authorization applications (CP/DCP/MRP/NS), technical dossiers, post-marketing authorization maintenance, variations, renewals, and notifications. For pharmaceutical companies requiring regulatory affairs support across multiple jurisdictions.
• Tech Transfer Services Turnkey solutions for product transfer and industrialization projects, starting with gap assessment on regulatory aspects, production processes, and analytical methods, through preparation and implementation into routine production, including transfers from development to routine production and between Astrea manufacturing sites. For pharmaceutical companies transferring products.
• Project Management Services Dedicated project management team covering technical projects, new product introductions (NPIs), and customer development projects with tailored solutions and efficient management of complex projects. For pharmaceutical customers needing coordinated program delivery.
• Storage and Distribution Services Storage and distribution capabilities under ambient, cold, and freeze conditions for drug substance and finished product, with -80°C to +5°C freeze and cold chain capabilities, plus export distribution to over 100 countries. For pharmaceutical companies requiring integrated storage and global distribution of finished product and active substance.

Quantifiable outcome

• Filling speed up to 200 units/min for sterile products
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• NextPharma: NextPharma is a European CDMO offering OSD, sterile, and biotech contract manufacturing services across multiple sites, comparable in scale and offering to Astrea.
• Recipharm: Recipharm is a Sweden-based European CDMO with broad OSD, sterile, and semi-solid capabilities across many sites, making it one of the closest direct competitors to Astrea's combined OSD and sterile offering.
• Fareva: Fareva is a French-headquartered CDMO with manufacturing across Europe covering sterile injectables, OSD, and APIs, closely mirroring Astrea's French manufacturing footprint and dual OSD/sterile service model.
• Hovione: Hovione is a Portugal-based CDMO offering contract development and GMP manufacturing for drug substance and drug product (including OSD and sterile), overlapping with Astrea's small-molecule drug product CDMO focus.
• Delpharm: Delpharm is a leading French CDMO offering contract development and manufacturing of sterile and solid dosage forms across multiple European sites, directly comparable to Astrea's French OSD and aseptic fill-finish network.
• Aenova: Aenova is a European CDMO specializing in solid, semi-solid, and sterile liquid dosage forms with multiple GMP sites, directly comparable to Astrea's OSD and aseptic manufacturing scope.

Broad incumbents

• Lonza: Lonza is a global CDMO with extensive sterile fill-finish and oral solid dose capacity across multiple continents, serving as a broad incumbent benchmark for Astrea's service portfolio and customer profile.
• Catalent: Catalent is a large global CDMO with broad OSD, softgel, and sterile fill-finish capabilities across many sites, representing a well-funded incumbent peer in Astrea's core service categories.

Emerging players

• Eurofins CDMO: Eurofins CDMO provides contract manufacturing and analytical services for small molecules including solid dose and sterile forms, an emerging player overlapping with Astrea's small-molecule CDMO scope.
• Centrient Pharmaceuticals (CDMO services): Centrient's manufacturing arm offers small-molecule API and finished dose manufacturing, partially overlapping with Astrea's small-molecule drug product CDMO positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/astrea-fontaine

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Astrea